The BioProtect Balloon Implant, now commercially available in Europe, is indicated for prostate cancer patients undergoing radiation therapy. The biodegradable balloon separates the prostate and rectum allowing physicians to radiate prostate tumors while sparing healthy rectal tissue. With the balloon implant, safe dose escalation and hypofractionation are finally possible, dramaticallydecreasing the chances of patient G2 rectal toxicity and improving biochemical tumor control.
About the BioProtect Balloon Implant
Enabling safe dose escalation and hypofractionation
The BioProtect Balloon Implant has the CE mark and is commercially available in Europe
BioProtect Balloon Implant presents huge advantages
Safe distance for dose escalation
A safe 1.8 cm distance between prostate and rectum is created enabling dose escalation and hypofractionation. This dramatically reduces the risk for radiation-related complications.
Visible under CT, Ultrasound and MRI
Balloon boundaries are highly visible under any imaging modality.
A confined structure with a defined volume enable reproducible separation.
Simple transperineal deployment is possible under local or general anesthesia.
No need to remove the balloon surgically as it biodegrades within six months from implantation.